Innovent's SYCUME Breakthrough Disrupts China's Surgical Monopoly in TED

SAN FRANCISCO and SUZHOU, China – October 08, 2026 — In the high-stakes arena of global biopharmaceuticals, competitive advantage is increasingly defined by a company's ability to localize innovation and dismantle legacy treatment paradigms. For decades, patients suffering from the chronic, inactive phase of Thyroid Eye Disease (TED) have faced a grim ultimatum: endure persistent facial disfigurement and visual impairment, or undergo highly invasive orbital decompression surgery. Today, that paradigm is shifting dramatically.

Innovent Biologics, Inc. (HKEX: 01801) has announced that its Phase 3 RESTORE-3 clinical trial for SYCUME® (teprotumumab N01 injection) met its primary and key secondary endpoints in Chinese patients with inactive TED. The results not only validate the efficacy of the recombinant anti-IGF-1R antibody in chronic disease states but also signal a broader strategic maneuver. By establishing comprehensive clinical parity with global benchmarks and securing national reimbursement, Innovent is rapidly fortifying a domestic moat that will be exceedingly difficult for foreign competitors to breach.

Ending the 70-Year Surgical Monopoly

Thyroid Eye Disease is a debilitating autoimmune condition that affects ocular tissues, most commonly associated with Graves' disease. Its natural progression is strictly bifurcated into an active inflammatory phase and a subsequent inactive, chronic phase. Historically, medical therapies were deemed futile once the acute inflammation subsided. Patients were left to manage the residual, often severe, structural damage—including proptosis (eye bulging), diplopia (double vision), and eyelid retraction—through complex corrective surgeries.

The RESTORE-3 trial data effectively challenges this long-standing surgical monopoly. Enrolling 116 Chinese participants with inactive TED (defined by a Clinical Activity Score of ≤ 2) and an average disease duration of 4.3 years, the study demonstrated that targeted pharmacological intervention can reverse tissue remodeling long after the inflammatory window has closed.

At Week 24, the proptosis response rate in the study eye was a remarkable 60.4% in the SYCUME cohort, compared to just 23.5% in the placebo group, representing a treatment difference of 36.9 percentage points (p = 0.0003). Furthermore, the least squares mean change from baseline in proptosis distance was -1.88 mm for patients receiving SYCUME, demonstrating a statistically significant superiority over the -0.88 mm reduction observed in the placebo group (p < 0.0001). Non-study eyes exhibited a similarly robust response, confirming the systemic efficacy of the targeted biologic.

Professor Zhongyan Shan from the First Hospital of China Medical University, the Lead Principal Investigator of the study, underscored the clinical gravity of these findings. "For a long time, effective pharmacological interventions for inactive TED have been lacking," Professor Shan stated. "At this stage, surgical intervention has been virtually the sole recourse, leading many patients to forgo treatment and endure the chronic burden of the disease. Results from this trial confirm that SYCUME® yields robust and clinically meaningful reductions in proptosis even in patients with chronic, inactive TED. This not only validates the therapeutic value of targeting IGF-1R in long-duration inactive TED, but also offers tens of thousands of chronic TED sufferers and clinicians a novel non-surgical treatment paradigm."

The Domestic Moat and Market Dynamics

From a commercial perspective, the RESTORE-3 readout is a masterclass in market expansion. Patients with inactive TED account for approximately two-thirds of the overall TED population. By successfully demonstrating efficacy in this chronic cohort, Innovent is effectively tripling the addressable market for SYCUME in China.

SYCUME originally received approval from China's National Medical Products Administration (NMPA) in March 2025 for the treatment of TED, filling a 70-year void in domestic pharmacological options. However, the true catalyst for its market dominance was its inclusion in China's National Reimbursement Drug List (NRDL) on January 1, 2026.

Before SYCUME, the global benchmark for IGF-1R inhibition in TED was Amgen's Tepezza, which carried a staggering launch price of approximately $14,900 per vial in the United States. By developing an indigenous alternative and securing NRDL coverage, Innovent has radically altered the economic equation of TED treatment in China. The state-backed reimbursement substantially alleviates the out-of-pocket burden for patients, seamlessly integrating the biologic into hospital procurement channels and standardizing its use as a first-line or second-line therapy over costly, high-risk surgeries.

Dr. Lei Qian, Chief R&D Officer of Innovent Biologics, highlighted the strategic importance of this dual approach. "As the first targeted therapy for TED approved and successfully incorporated into the NRDL in China, SYCUME® has already benefited a vast number of TED patients," Dr. Qian noted. "With these positive Phase III trial results, SYCUME® now achieves comprehensive disease coverage ranging from 'early acute control' to 'chronic phase tissue remodeling.'"

Clinical Parity and the Safety Equation

For investors and industry analysts, the critical question has always been whether domestic Chinese biopharmaceuticals can achieve true clinical parity with their Western counterparts. The RESTORE-3 data provides compelling affirmative evidence.

While direct cross-trial comparisons require methodological caution, Innovent reported that SYCUME's proptosis response rate and reduction metrics were generally consistent with the data generated by Tepezza in inactive TED populations, despite the Chinese cohort presenting with a lower baseline mean proptosis. This parity is crucial for establishing physician trust and driving rapid commercial adoption.

Equally vital is the safety profile. The IGF-1R inhibitor class is known for specific adverse events, including muscle spasms, hyperglycemia, and hearing impairment. In the RESTORE-3 double-blind treatment and follow-up period, Innovent reported that SYCUME exhibited good safety and tolerability. Most treatment-emergent adverse events were categorized as mild to moderate, and crucially, no new safety signals were identified. As real-world application scales up following NRDL inclusion, rigorous post-market surveillance will be essential to ensure these class-specific risks remain manageable within the broader Chinese population.

The Path Forward for Label Expansion

The positive Week 24 data sets the stage for Innovent to submit a supplemental Biologics License Application (sBLA) to the NMPA, seeking a formal label expansion for SYCUME to include inactive TED. Given the drug's existing regulatory standing and the overwhelming unmet medical need, the review process is anticipated to be highly prioritized.

This development is emblematic of a broader macroeconomic trend shaping the 2026 landscape: the aggressive de-risking of healthcare supply chains. China is no longer content to rely on the delayed importation of expensive Western therapeutics. Through companies like Innovent—which boasts a pipeline of 19 early-stage molecules and strategic partnerships valued at over RMB 350 billion—the nation is fostering a self-sustaining ecosystem of high-quality, affordable biopharmaceuticals.

As the clinical community prepares to translate the RESTORE-3 findings into standard practice, the implications extend far beyond the realm of ophthalmology. Innovent has demonstrated that by combining targeted biological innovation with shrewd regulatory and reimbursement strategies, domestic firms can effectively rewrite the rules of global pharmaceutical competition, securing lasting advantages in one of the world's most critical markets.